Institutional investors hold a majority ownership of MYGN through the 120.07% of the outstanding shares that they control. This interest is also higher than at almost any other company in the Biotechnology industry. Last, during the quarter ended December 2016, these large investors purchased a net $1.0 million shares.
Mutual fund holders
Largest Quarterly Institutional Transactions
Latest Institutional Activity
CAMBER CAPITAL MANAGEMENT LLC Bought 4.1 Million shares of Myriad Genetics Inc
CONSONANCE CAPITAL MANAGEMENT LP Bought 1.5 Million shares of Myriad Genetics Inc
RUSSELL INVESTMENT MANAGEMENT LL... Bought 1.1 Million shares of Myriad Genetics Inc